ABL Diagnostics reaches first milestone in MyNadis digital health push

ABL Diagnostics said it completed the first development and operational validation phase of MyNadis, a mobile app for patients built with a major international pharmaceutical partner. The milestone deepens the French company’s move into digital health as it expands on the Nadis platform used to track infectious-disease care.

Why it matters: - ABL Diagnostics is broadening beyond molecular diagnostics into digital health, a market shaped by the digitization of care pathways and growing use of health data. - MyNadis is meant to improve how patients and care teams share information during treatment and follow-up. - The move builds on nearly a decade of work on Nadis, a platform already used in infectious-disease care, including HIV.

What happened: - ABL Diagnostics announced the successful completion of the first development and operational validation phase of MyNadis. - MyNadis is a new secure mobile app for patients. - The app was developed with a major international pharmaceutical company. - The announcement came from ABL Diagnostics in Woippy, France, on July 15, 2026.

The details: - MyNadis gives patients access to certain documents and information shared by health professionals. - The app lets patients view biological test results sent by medical teams. - MyNadis can display information related to care-pathway follow-up. - Hospitals can configure notifications and reminders inside the app. - The platform is designed to make exchanges between patients and health professionals easier. - Nadis and MyNadis use infrastructure that meets European data-protection requirements. - The systems use HDS-certified hosting and processes aligned with GDPR requirements. - ABL Diagnostics said Nadis has been deployed in many hospitals in France and in several French-speaking African countries. - The company said the platform is modular and interoperable, which supports adaptation to different health environments. - ABL Diagnostics said it is also studying new digital functions, including data analytics and artificial intelligence, while staying within applicable regulatory frameworks. - The company’s website is More information.

Between the lines: - The MyNadis launch signals a deeper push to turn ABL Diagnostics’ infectious-disease software base into a broader digital-health business. - The company is leaning on an existing installed base and operational know-how rather than starting from scratch. - The focus on secure hosting, GDPR compliance and hospital workflows suggests the product is being positioned for regulated clinical settings, not consumer wellness use.

What's next: - ABL Diagnostics said it will keep developing its digital ecosystem after this first milestone. - The company plans a gradual rollout of additional digital features. - ABL Diagnostics is exploring future AI-based capabilities for data analysis and use, subject to regulatory approval and compliance. - The company sees opportunities to expand with new hospitals and partners in France and abroad.

The bottom line: - MyNadis gives ABL Diagnostics a first concrete step from diagnostic software into a wider digital-health platform built around patient engagement and care coordination.